Clear Rock Advisors LLC Boosts Stock Position in Humana Inc. (NYSE:HUM)

Clear Rock Advisors LLC boosted its stake in shares of Humana Inc. (NYSE:HUM) by 4.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,131 shares of the insurance provider’s stock after purchasing an additional 199 shares during the quarter. Clear Rock Advisors LLC’s holdings in Humana were worth $1,779,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Rakuten Securities Inc. acquired a new stake in shares of Humana in the 4th quarter valued at about $25,000. Cetera Trust Company N.A acquired a new stake in Humana during the 4th quarter worth approximately $28,000. Private Wealth Management Group LLC acquired a new stake in Humana during the 4th quarter worth approximately $32,000. Carolinas Wealth Consulting LLC lifted its position in Humana by 274.1% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after acquiring an additional 74 shares during the period. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in Humana during the 4th quarter worth approximately $55,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on HUM shares. Piper Sandler started coverage on Humana in a research report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price objective for the company. Oppenheimer increased their price objective on Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday. Bank of America increased their target price on Humana from $342.00 to $376.00 and gave the stock a “neutral” rating in a research note on Monday, May 20th. Wells Fargo & Company cut their target price on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research note on Monday, April 8th. Finally, Truist Financial increased their target price on Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research note on Monday, July 15th. Fourteen equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $403.55.

Humana Trading Up 1.3 %

Shares of HUM stock traded up $4.64 during mid-day trading on Friday, hitting $363.62. 1,076,306 shares of the company’s stock were exchanged, compared to its average volume of 1,396,067. Humana Inc. has a fifty-two week low of $298.61 and a fifty-two week high of $530.54. The stock has a 50-day simple moving average of $367.90 and a two-hundred day simple moving average of $347.51. The company has a quick ratio of 1.67, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The stock has a market cap of $43.78 billion, a price-to-earnings ratio of 22.64, a PEG ratio of 2.09 and a beta of 0.51.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter last year, the firm earned $8.94 earnings per share. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. Equities analysts expect that Humana Inc. will post 16.14 EPS for the current fiscal year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.